Abstract:Klisyri (KX01) is a dual tubulin/Src protein inhibitor that has shown potential therapeutic effects in several tumor models. However, a phase II clinical trial in patients with bone-metastatic castration-resistant prostate cancer was halted because of lack of efficacy. We previously reported that KX01 binds to the colchicine site of β-tubulin and its morpholine group lies close to α-tubulin's surface. Thus, we hypothesized that enhancing the interaction of KX01 with α-tubulin could increase tubulin inhibition and synthesized a series of KX01 derivatives directed by docking studies. Among these derivatives, 8a exhibited more than 10-fold antiproliferation activity in several tumor cells than KX01 and significantly improved in vivo antitumor effects. The X-ray crystal structure suggested that 8a both bound to the colchicine site and extended into the interior of α-tubulin to form potent interactions, presenting a novel binding mode. A potential clinical candidate for cancer therapy was identified in this study.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01961?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01961</a>.Characterization of key compounds, antiproliferation activity data, MTD, table of protein crystal data collection and refinement statistics, and HPLC purity traces for key final compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_001.pdf">PDF</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_002.csv">CSV</a>)Structural data for compounds 6a, 6d, and 6r (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_003.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_004.pdb">PDB</a>) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01961/suppl_file/jm0c01961_si_005.pdb">PDB</a>)This article has not yet been cited by other publications.

Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor

Optimization of a series of potent, selective and orally bioavailable SYK inhibitors

Discovery of 3-(1H-benzo[d]imidazole-2-yl)-1h-pyrazol-4 -Amine Derivatives As Novel and Potent Syk Inhibitors for the Treatment of Hematological Malignancies.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis and Antitumor Evaluation of a New Series of N-substituted-thiourea Derivatives

Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors

Spleen tyrosine kinase (SYK): an emerging target for the assemblage of small molecule antitumor agents

Identification of pyrazolopyridine derivatives as novel spleen tyrosine kinase inhibitors.

Discovery of TK-642 as a highly potent, selective, orally bioavailable pyrazolopyrazine-based allosteric SHP2 inhibitor

Design, synthesis and biological evaluation of a series of novel pyrrolo[2, 3-d] pyrimidin/pyrazolo[3, 4-d] pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer

Synthesis and biological evaluation of 6-(pyrimidin-4-yl)-1H-pyrazolo[4,3-b]pyridine derivatives as novel dual FLT3/CDK4 inhibitors

Discovery of New Syk Inhibitors Through Structure-Based Virtual Screening.

Discovery of 12O-A Novel Oral Multi-Kinase Inhibitor for the Treatment of Solid Tumor

Design, Synthesis and Biological Evaluation of Novel 2,4-Diaryl Pyrimidine Derivatives As Selective EGFRL858R/T790M Inhibitors.

Design, synthesis and biological evaluation of a series of novel pyrrolo[2,3-d]pyrimidin/pyrazolo[3,4-d]pyrimidin-4-amine derivatives as FGFRs-dominant multi-target receptor tyrosine kinase inhibitors for the treatment of gastric cancer

Discovery and SARs of 5-Chloro-n4-phenyl-n2-(pyridin-2-yl)pyrimidine-2,4-diamine Derivatives As Oral Available and Dual CDK 6 and 9 Inhibitors with Potent Antitumor Activity

Design, Synthesis, and Bioactivity Evaluation of Dual-Target Inhibitors of Tubulin and Src Kinase Guided by Crystal Structure

Design and Synthesis of Novel Pyrrolo[2,3-D]pyrimidine Derivatives As Potent JAK3 and SYK Dual Inhibitors

Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase

Design, Synthesis and Biological Evaluation of Novel Antitumor Spirodihydrothiopyran-Oxindole Derivatives